Related Experiment Video
Updated: Feb 5, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Overcoming Organizational Challenges of Integrating Patient-Reported Outcomes in Oncology Clinical Trials
Ari Gnanasakthy1, Carla DeMuro1
11 RTI Health Solutions, Research Triangle Park, NC, USA.
Abstract:
Patients with cancer frequently experience multiple symptoms that may cause significant distress and may impair physical, emotional, and social functioning and health-related quality of life. Drug development in oncology is characterized by a high attrition rate of new compounds, faster development times encouraged by the regulatory process, studies that are often open and single-arm, and emphasis on survival-related endpoints, creating unique challenges for the inclusion of patient reported outcomes (PROs). These challenges to include PRO-related endpoints in oncology research are further exacerbated by downward pressure on budget and resources and also an overly rigorous application of the US Food and Drug Administration's PRO guidance, which can in turn prevent study teams from optimally including PROs in oncology clinical trials. With increasing calls for demonstration of value of new cancer drugs from payers, patients, and their caregivers, study teams should consider the utility of PROs beyond regulatory needs. Optimal implementation of a PRO strategy in oncology research can be achieved by applying the PRO guidance to the greatest extent possible, making use of off-the-shelf PRO measures to capture concepts of interest, discussing plans with the regulatory bodies early in the process, and treating PRO-related endpoints with the same level of rigor as other endpoints.
Insights
Patient-reported outcomes (PROs) are crucial for cancer drug development but face implementation challenges. Optimizing PROs requires rigorous application of guidance and strategic planning beyond regulatory requirements.
Area of Science:
- Oncology
- Clinical Trial Design
- Patient-Reported Outcomes
Background:
- Cancer patients often experience multiple distressing symptoms impacting quality of life.
- Oncology drug development faces unique challenges for incorporating patient-reported outcomes (PROs) due to high attrition rates, rapid development, and survival-focused endpoints.
Purpose of the Study:
- To address the challenges in implementing patient-reported outcomes (PROs) in oncology clinical trials.
- To provide recommendations for optimizing the inclusion and utilization of PROs in cancer drug development.
Main Methods:
- Review of challenges in PRO integration within oncology research.
- Analysis of regulatory guidance and resource pressures affecting PRO implementation.
- Discussion of strategies for optimal PRO strategy development.
Main Results:
- Rigorous application of US Food and Drug Administration's PRO guidance can be challenging.
- Budgetary constraints and regulatory interpretations can hinder optimal PRO inclusion.
- PROs offer value beyond regulatory needs, essential for demonstrating drug value.
Conclusions:
- Optimal PRO implementation in oncology requires strategic planning and adherence to guidance.
- Utilizing off-the-shelf PRO measures and early regulatory discussions are key.
- Treating PRO endpoints with the same rigor as other trial endpoints is essential for robust oncology research.
More Related Videos
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Statistical Software for Data Analysis and Clinical Trials
Data Reporting and Recording
Trial and Error and Algorithm
Levels of Communication II: Organizational, Public, and Group Dynamics

